Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Gloomy predictions about the future of pharma have forced the industry to investigate alternative models of drug discovery. Public-private partnerships (PPPs) have the potential to revitalize the discovery and development of first-in-class therapeutics. The new PPP Arch2POCM hopes to foster biomedical innovation through precompetitive validation of pioneer therapeutic targets for human diseases. In this meeting report, we capture insights garnered from the April 2011 Arch2POCM conference.

Original publication

DOI

10.1126/scitranslmed.3002678

Type

Journal article

Journal

Sci Transl Med

Publication Date

22/06/2011

Volume

3

Keywords

Clinical Trials as Topic, Drug Discovery, Drug Industry, Humans, Private Sector, Public-Private Sector Partnerships